Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting

Supportive Care in Cancer

Volumn 20, Issue 3, 2012, Pages 653-656

  Hesketh, Paul J ^a   Sanz Altamira, Pedro ^b  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b Commonwealth Hematology Oncology ^*  (United States)

Author keywords

Aprepitant; Breast cancer; Nausea; Palonosetron; Vomiting

Indexed keywords

APREPITANT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; PALONOSETRON;

ADULT; AGED; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; MORNING DOSAGE; NAUSEA; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; ISOQUINOLINES; MIDDLE AGED; MORPHOLINES; NAUSEA; PILOT PROJECTS; QUINUCLIDINES; VOMITING;

EID: 84857650806     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1312-8     Document Type: Article

References (11)

1. PJ Hesketh 2008 Chemotherapy-induced nausea and vomiting N Engl J Med 358 23 2482 2494 18525044 10.1056/NEJMra0706547 1:CAS:528:DC%2BD1cXmvFKltL0%3D (Pubitemid 351793021)
2. F Roila J Herrstedt M Aapro, et al. 2010 Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference Ann Oncol 21 Suppl 5 v232 v243 20555089 10.1093/annonc/mdq194
3. DG Warr PJ Hesketh RJ Gralla, et al. 2005 Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy J Clin Oncol 23 2822 2830 15837996 10.1200/JCO.2005.09.050 1:CAS:528: DC%2BD2MXktleqt74%3D [Erratum, J Clin Oncol 2005; 23:5851.] (Pubitemid 46179473)
4. LP Yang LJ Scott 2009 Palonosetron: in the prevention of nausea and vomiting Drugs 69 2257 2278 19852528 10.2165/11200980-000000000-00000 1:CAS:528:DC%2BD1MXhsFOqtr7E
5. R Gralla M Lichinitser S Van Der Vegt, et al. 2003 Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann Oncol 14 1570 1577 14504060 10.1093/annonc/mdg417 1:STN:280:DC%2BD3svktlKitQ%3D%3D (Pubitemid 37304615)
6. P Eisenberg J Figueroa-Vadillo R Zamora, et al. 2003 Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron Cancer 98 2473 2482 14635083 10.1002/cncr.11817 1:CAS:528:DC%2BD3sXpvFOrt70%3D (Pubitemid 37466663)
7. M Saito K Aogi I Sekine, et al. 2009 Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomized, comparative phase III trial Lancet Oncol 10 115 124 19135415 10.1016/S1470-2045(08)70313-9 1:CAS:528:DC%2BD1MXhtlGlurk%3D
8. T Grote J Hajdenberg A Cartmell, et al. 2006 Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone and aprepitant J Support Oncol 4 403 408 17004515 1:CAS:528:DC%2BD28XhtVKntr7L (Pubitemid 44541016)
9. JD Herrington AD Jaskiewicz J Song 2008 Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting Cancer 112 2080 2087 18327813 10.1002/cncr.23364 1:CAS:528:DC%2BD1cXmtFOlu7s%3D (Pubitemid 351574085)
10. SM Grunberg M Dugan H Muss, et al. 2009 Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy Support Care Cancer 17 589 594 19037667 10.1007/s00520-008-0535-9
11. PJ Hesketh MG Kris SM Grunberg, et al. 1997 Proposal for classifying the acute emetogenicity of cancer chemotherapy J Clin Oncol 15 103 109 8996130 1:STN:280:DyaK2s7kvFehsA%3D%3D (Pubitemid 27020563)